Evercore ISI’s decision to lift its price target on
📊 INTERESTING: Robinhood's tokenized stocks just crossed 40,000 holders after a 10x weekly surge.News | Markets | YouTube
Yahoo Finance · 2026-07-11 20:35 UTC · Summary by Aunhelloworld
Key takeaways
- Evercore ISI has increased its valuation forecast for Twist Bioscience, signalling a more optimistic view of the company’s future earnings.
- Twist Bioscience’s core business – high‑throughput DNA synthesis – is positioned to benefit from growing demand in genomics, pharmaceuticals and synthetic biology.
- The upgrade comes amid a broader market environment that is still dominated by extreme fear, as shown by the current fear‑greed index.
- Crypto markets are only modestly up (BTC +1.06 %, ETH +2.56 %) and largely insulated from the biotech rally, but risk appetite can spill over into riskier assets.
- Regulatory headlines such as Polymarket’s US licence application and the upcoming CBDC ban suggest that policy developments will continue to shape market sentiment.
Market context (crypto.bagg.uk)
| Pair | Price (USDT) | 24h |
|---|---|---|
| BTC/USDT | $63854.38000000 | 1.0642% |
| ETH/USDT | $1790.98000000 | 2.5591% |
Original editorial by Aunhelloworld — based on the headline and excerpt plus live market data from crypto.bagg.uk. Not financial advice. Verify facts at the source.